Effectiveness of a Cognitive Training Program (UMAM Method) in Elderly People Without Dementia
25 de janeiro de 2020 atualizado por: Madrid Salud
Cognitive Training in Elders Without Dementia Using UMAM Method. Genetic, Brain Volume and Cognitive Reserve Predictors: A Randomized Controlled Study
The study is oriented to analyze the effectiveness of a cognitive training method (UMAM) on cognitive functions, subjective memory and mood state in elderly people without dementia.
On the other hand, the study aims to examine whether variables such as cognitive reserve (e.g.
educational level), APOE genotype and intracranial volume are related to increased benefit after the intervention.
The researchers hope to find that greater cognitive reserve, not having the APOE allele ε4, and a greater volume of memory-related brain areas, are associated with better outcomes after the cognitive intervention.
Visão geral do estudo
Status
Concluído
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
199
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Madrid, Espanha, 28006
- Centro de Prevención del Deterioro Cognitivo
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
60 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Being over 60 years old.
- Having a global cognitive performance > 23 in the Mini Mental State Examination Test.
- Having no history of neurological or serious psychiatric disorders (severe psycho-affective disorders and psychosis or other psychiatric disorders like alcoholism).
Exclusion Criteria:
- Chronic use of anxiolytics.
- Chronic use of neuroleptics.
- Chronic use of anticonvulsants.
- Having hearing or vision impairments that would preclude testing.
- Magnetic Resonance Imaging (MRI) contraindications.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental Group
The experimental group carried out a 30-session multi-factorial group memory training program (UMAM method), with a frequency of three weekly sessions of 90 minutes each. The training program consists of four modules: 1- Stimulation of cognitive processes; learning and practicing internal memory strategies and solving everyday forgetfulness; 2- Instruction in basic concepts about memory; 3- Intervention on daily living and forgetting experiences, using internal and external strategies to solve everyday memory failures; 4- Metacognition or metamemory: the subjects were to reflect about their cognitive failures by analyzing the causes and variables of those failures. In addition, the experimental group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.). |
|
|
Sem intervenção: Control Group
The Control Group followed the standard activities in which all users attending the Center are involved (planned interviews, dialogue-conferences, general health recommendations, etc.).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in general cognition
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in general cognition, assessed with the Mini Mental State Examination Test (MMSE) and the 7 Minutes Test (7M).The score ranges from 0 to 30 points (MMSE) and from 0 to 89 points (7M).
In both cases, the higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in verbal memory
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in verbal memory, assessed with the Word List Test of the Wechsler Memory Scale-III.
The score ranges from 0 to 48 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in logical memory
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in immediate and delayed logical memory, assessed with the Logical Memory Test (immediate and delayed units) of the Wechsler Memory Scale-III.
The score ranges from 0 to 75 points (immediate units) and from 0 to 50 (delayed units).
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in visual memory
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in visual memory, assessed with the Rey memory test (form B).
The score ranges from 0 to 22 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in daily memory
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in daily memory, assessed with the Rivermead Behavioral Memory Test.
The score ranges from 0 to 24 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in attentional amplitude
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in attentional amplitude, assessed with the Direct Digit Test of the Wechsler Memory Scale-III.
The score ranges from 0 to 16 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in attentional control
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in attentional control, assessed with the Inverse Digit Test of the Wechsler Memory Scale-III.
The score ranges from 0 to 14 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in attention and processing speed
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in attention, assessed with the Trail Making Test, form A. The score ranges from 0 to 200 points.
Higher scores indicate a worse outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in alternating attention and planning
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in alternating attention and planning, assessed with the Trail Making Test, form B. The score ranges from 0 to 400 points.
Higher scores indicate a worse outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in naming ability (language)
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in naming ability, assessed with the Boston Naming Test.
The score ranges from 0 to 60 points.
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in verbal fluency (language)
Prazo: This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in phonologic and semantic verbal fluency, assessed with the Phonological Verbal Fluency Test and the Semantic Fluency Test respectively.
The score goes from zero onwards (there is no upper limit).
Higher scores indicate a better outcome.
|
This cognitive variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in subjective memory
Prazo: This variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in Subjective Memory, assessed with the Memory Failures of Everyday Questionnaire.The score ranges from 0 to 56 points.
Higher scores indicate a worse outcome.
|
This variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
Change in mood
Prazo: This variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
The measure of the post-intervention change in mood, assessed with the Geriatric Depression Scale.
The score ranges from 0 to 15 points.
Higher scores indicate a worse outcome.
|
This variable was assessed before and after the intervention. The interval between the pre and post-intervention assessment was 6 months.
|
|
The Cognitive Reserve as a predictor of change.
Prazo: Cognitive Reserve was assessed in the pre-intervention assessment.
|
The Cognitive Reserve was assessed with Rami Test.
The score ranges from 0 to 25 points.
|
Cognitive Reserve was assessed in the pre-intervention assessment.
|
|
The Genetic Profile as a predictor of change.
Prazo: The Genetic Profile was assessed in the pre-intervention assessment.
|
The Genetic Profile was obtained by genetic analysis employing a blood test.
APOE gene has been coded as 1 (meaning no ε4 allele), or 0 (for at least one ε4 allele).
|
The Genetic Profile was assessed in the pre-intervention assessment.
|
|
The Brain Volume as a predictor of change.
Prazo: The Brain Volume was assessed in the pre-intervention assessment.
|
The Brain Volume (total gray volume, left hippocampus, right hippocampus and total intracranial volume) was assessed by magnetic resonance imaging.
Unit of measure: mm3.
|
The Brain Volume was assessed in the pre-intervention assessment.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de outubro de 2013
Conclusão Primária (Real)
1 de maio de 2015
Conclusão do estudo (Real)
1 de maio de 2015
Datas de inscrição no estudo
Enviado pela primeira vez
22 de dezembro de 2019
Enviado pela primeira vez que atendeu aos critérios de CQ
25 de janeiro de 2020
Primeira postagem (Real)
29 de janeiro de 2020
Atualizações de registro de estudo
Última Atualização Postada (Real)
29 de janeiro de 2020
Última atualização enviada que atendeu aos critérios de controle de qualidade
25 de janeiro de 2020
Última verificação
1 de janeiro de 2020
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 15/382-E_BS
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Não
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
produto fabricado e exportado dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .